ST. LOUIS, Sept. 28, 2011 /PRNewswire/ — Monsanto Company (NYSE: MON) today announced it has acquired Beeologics, which researches and develops biological tools to provide targeted control of pests and diseases. Terms of the deal were not disclosed.

Beeologics is focused on biological research. Current projects in its pipeline – including a product candidate being developed to help protect bee health – use a naturally-occurring process to provide targeted pest and disease control.

The expertise Beeologics has developed will enable Monsanto to further explore the use of biologicals broadly in agriculture. Monsanto will use the base technology from Beeologics as a part of its continuing discovery and development pipeline. Biological products will continue to play an increasingly important role in supporting the sustainability of many agricultural systems. Both companies expect that their combined research could provide farmers with novel approaches to the challenges they face.

Monsanto, which has proven expertise in managing a technology pipeline, will support the Beeologics team and its Technology Advisory Board in advancing its pipeline. Beeologics’ work to promote bee health will continue under Monsanto’s ownership.

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world’s natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com. Follow our business on Twitter at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows at www.monsantoblog.com, or subscribe to our News Release RSS Feed.

About Beeologics

Beeologics is an international firm dedicated to restoring bee health and protecting the future of insect pollination. Through continuous research, scientific innovation, and a focus on applicable solutions, Beeologics is developing a line of products to specifically address the long-term well being of the bees. With offices and laboratories in the United States and Israel, Beeologics brings together some of the world’s most recognized scientists in its field to help achieve its mission. To learn more about Beeologics, please visit: www.beeologics.com.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are “forward-looking statements,” such as statements concerning the company’s anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: competition in seeds, traits and agricultural chemicals and animal drugs; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory submissions, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company’s research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing, labeling and promotion; the accuracy of the company’s estimates related to distribution inventory levels; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture and animal drug business or the company’s facilities; and other risks and factors detailed in the company’s most recent Form 10-K Report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

CONTACT | Kelli Powers (314-694-4003)

SOURCE Monsanto Company